Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyMolina Tzield Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedMolina HealthcarePolicy C24729-A

    Tzield (teplizumab-mzwv) Coverage Criteria

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C24729-A alerts

    Get alerted when Policy C24729-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Molina Healthcare coverage and prior authorization for intravenous Tzield in members with Stage 2 or recently diagnosed Stage 3 type 1 diabetes. Coverage requires diagnosis-specific clinical documentation, age eligibility, endocrinology prescribing or consultation, and administration in a non-hospital facility-based setting.

    Policy Summary
    PayerMolina Healthcare
    PolicyTzield (teplizumab-mzwv) Coverage Criteria
    Policy CodePolicy C24729-A
    Change TypeModified
    Effective DateSep 24, 2026
    Next Review DateApr 1, 2027
    Key ActionEnsure Tzield is prescribed by or in consultation with a board-certified endocrinologist and submit consultation notes with the initial request when applicable.
    SourceLink
    POLICY UPDATE CHANGES

    The Q3 2026 revision history identifies updates to required medical information, age restrictions, FDA-approved uses, the appendix, background, contraindications/exclusions/discontinuation, other special considerations, and references.

    The Q2 2026 revision history identifies updates to required medical information and place-of-administration content.

    Stage 2 T1DCovered indication
    Stage 3 T1DCovered indication
    14 daysStage 2 treatment course

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Two 12-day coursesStage 3 treatment schedule
    Ages 1+Stage 2 age eligibility
    Ages 8-17Stage 3 age eligibility

    Coverage Criteria

    Initial Therapy: Stage 2 Type 1 Diabetes

    Covered when ALL of the following are met:

    Stage 2 Type 1 Diabetes

    • Autoantibodies: Stage 2 T1D is confirmed by two positive pancreatic islet autoantibodies2 positive antibodies

      Acceptable antibodies include GAD, IAA, IA-2A, ZnT8A, and ICA

    • Dysglycemia: Member has dysglycemia without overt hyperglycemia documented by an oral glucose tolerance test within the last 60 days, or an appropriate alternative method when an oral glucose tolerance test is unavailableFasting glucose 100–125 mg/dL; or 2-hour postprandial glucose ≥140 mg/dL and <200 mg/dL; or intervening postprandial glucose >200 mg/dL at 30, 60, or 90 minutes on two occasions

      Documentation required

    • Type 2 diabetes excluded: The member's clinical history does not suggest type 2 diabetes

    Initial Therapy: Stage 3 Type 1 Diabetes

    Covered when ALL of the following are met:

    Stage 3 Type 1 Diabetes

    • Recently diagnosed Stage 3 T1D: Member has recently diagnosed Stage 3 type 1 diabetesDiagnosis within the past 6 weeks

      Documentation required

    • Autoantibody confirmation: Stage 3 T1D is confirmed by one positive pancreatic islet autoantibody1 positive antibody

      Documentation required

    • Preserved beta-cell function: Member has preserved pancreatic beta-cell function confirmed by peak C-peptide on a mixed-meal tolerance test, or an appropriate alternative method when the test is unavailable

    Non-FDA-approved uses of Tzield (teplizumab-mzwv) are considered experimental or investigational and are handled under Molina’s Off-Label policy.

    Tzield should not be used in patients who are immunocompromised or who have an active viral infection, including Epstein-Barr virus (EBV) or cytomegalovirus (CMV) infection.

    Avoid Tzield during pregnancy and for at least 30 days before a planned pregnancy.

    Use of Tzield is not recommended with specified laboratory abnormalities, including lymphocyte count below 1,000/mcL, hemoglobin below 10 g/dL, platelet count below 150,000/mcL, or absolute neutrophil count below 1,500/mcL. It is also not recommended when ALT or AST exceeds 2 times the upper limit of normal or bilirubin exceeds 1.5 times the upper limit of normal.

    Tzield is not recommended for patients with an active serious infection or a chronic active infection, except for localized skin infections. Patients should be monitored for infection during and after treatment; discontinue Tzield if a serious infection develops.

    Coding and Clinical Thresholds

    HCPCS CodeHCPCS
    J9381Injection, teplizumab-mzwv, 5 mcg
    Fasting glucose
    Threshold100 to 125 mg/dL
    SI equivalent5.6 to 6.9 mmol/L
    Clinical contextFasting glucose is one qualifying measure of dysglycemia without overt hyperglycemia.
    2-hour postprandial plasma glucose
    Lower thresholdAt least 140 mg/dL
    Upper thresholdLess than 200 mg/dL
    SI equivalentsAt least 7.8 mmol/L and less than 11.1 mmol/L

    Prior Authorization and Documentation

    Prior Authorization

    Endocrinologist Involvement Required

    Ensure Tzield is prescribed by, or prescribed in consultation with, a board-certified endocrinologist.

    Prior Authorization

    Age Eligibility

    Verify that the member meets the age requirement for the requested disease stage.

    • Stage 2 T1D: 1 year of age and older.
    • Stage 3 T1D: 8 to 17 years of age.
    Prior Authorization

    Authorization Duration

    Request authorization for the applicable treatment duration and course limits.

    Background

    Tzield (teplizumab-mzwv) is an intravenous anti-CD3 antibody used in selected patients with type 1 diabetes. FDA-approved uses include delaying the onset of Stage 3 type 1 diabetes in adults and pediatric patients aged 1 year and older with Stage 2 type 1 diabetes, and delaying the decline in endogenous insulin production in pediatric patients aged 8 through 17 years with recently diagnosed Stage 3 type 1 diabetes.

    Definitions

    Dysglycemia
    Fasting glucose100 to 125 mg/dL (5.6 to 6.9 mmol/L)
    2-hour postprandial glucoseAt least 140 mg/dL (7.8 mmol/L) and less than 200 mg/dL (11.1 mmol/L)
    Intervening postprandial glucoseGreater than 200 mg/dL at 30, 60, or 90 minutes on two occasions
    Pancreatic islet autoantibodies
    GAD autoantibodiesGlutamic acid decarboxylase 65 (GAD) autoantibodies
    Insulin-related antibodiesInsulin autoantibody (IAA)
    Additional antibodies

    Initial Therapy Criteria

    Stage 2 T1D

    Covered when ALL of the following diagnostic criteria are met:

    Stage 2 T1D criteria: Stage 2 T1D is confirmed by two positive pancreatic islet autoantibodies; dysglycemia without overt hyperglycemia documented by an oral glucose tolerance test within the last 60 days, or an appropriate alternative method when unavailable; and a clinical history that does not suggest type 2 diabetesTwo positive autoantibodies; fasting glucose 100–125 mg/dL, or 2-hour postprandial glucose ≥140 mg/dL and <200 mg/dL, or intervening postprandial glucose >200 mg/dL at 30, 60, or 90 minutes on two occasions

    Acceptable antibodies include GAD, IAA, IA-2A, ZnT8A, and ICA; documentation required

    Stage 3 T1D

    Covered when ALL of the following diagnostic criteria are met:

    Stage 3 T1D criteria: Member has recently diagnosed Stage 3 T1D, confirmed by one positive pancreatic islet autoantibody, and has preserved pancreatic beta-cell function

    Quantity Limits and Dosing

    Tzield Stage 2 dosing schedule
    Days 1-2Day 1: 65 mcg/m²; Day 2: 125 mcg/m²
    Days 3-4Day 3: 250 mcg/m²; Day 4: 500 mcg/m²
    Days 5-141,030 mcg/m² each day
    Tzield Stage 2 course limit
    Lifetime limitOne 14-day course per member lifetime
    Authorization durationInitial authorization is 3 months for Stage 2 T1D
    ContinuationContinuation of therapy is not applicable

    Site of Care

    Billing Rule

    Use an appropriate infusion site

    Administer the infused medication in a non-hospital facility-based location under pharmacy or medical benefit coverage.

    Policy Summary
    PayerMolina Healthcare
    PolicyTzield (teplizumab-mzwv) Coverage Criteria
    Policy CodePolicy C24729-A
    Change TypeModified
    Effective DateSep 24, 2026
    Next Review DateApr 1, 2027
    Key ActionEnsure Tzield is prescribed by or in consultation with a board-certified endocrinologist and submit consultation notes with the initial request when applicable.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsPrior Authorization and DocumentationBackgroundDefinitionsInitial Therapy CriteriaQuantity Limits and DosingSite of Care
    Peak C-peptide ≥0.2 pmol/mL

    Documentation required; see Appendix

    Intervening postprandial glucose
    ThresholdGreater than 200 mg/dL
    TimingMeasured at 30, 60, or 90 minutes after the meal
    ConfirmationRequired on two occasions
    Peak C-peptide
    Minimum peak C-peptideAt least 0.2 pmol/mL
    PurposeConfirms preserved pancreatic beta-cell function
    Preferred assessmentMeasured on a mixed-meal tolerance test
    Lymphocyte count
    Not recommended below1,000 lymphocytes/mcL
    Policy thresholdLymphocyte count less than 1,000 lymphocytes/mcL
    Assessment timingInclude the result in the baseline laboratory assessment
    Hemoglobin
    Not recommended below10 g/dL
    Policy thresholdHemoglobin less than 10 g/dL
    Assessment timingInclude the result in the baseline laboratory assessment
    Platelet count
    Not recommended below150,000 platelets/mcL
    Policy thresholdPlatelet count less than 150,000 platelets/mcL
    Assessment timingInclude the result in the baseline laboratory assessment
    Absolute neutrophil count
    Not recommended below1,500 neutrophils/mcL
    Policy thresholdAbsolute neutrophil count less than 1,500 neutrophils/mcL
    Assessment timingInclude the result in the baseline laboratory assessment
    ALT or AST
    Not recommended above2 times the upper limit of normal
    Tests includedALT or AST
    Assessment timingInclude liver enzyme results in the baseline laboratory assessment
    Bilirubin
    Not recommended above1.5 times the upper limit of normal
    TestBilirubin
    Assessment timingInclude the result in the baseline laboratory assessment
    • Stage 2 T1D: 3 months; one 14-day course per member lifetime.
    • Stage 3 T1D: 12 months; two 12-day courses, 6 months apart.
    • Continuation authorization is not applicable for either stage.

    Unsupported block type: prior_auth

    Documentation Required

    Complete Medical Necessity Documentation

    Submit complete medical-necessity documentation and supporting records. Molina may request additional patient records, test results, provider credentials, or member-specific dosing information and may deny or take other action when documentation does not support medical necessity, non-investigational use, benefit eligibility, or appropriate practice.

    • Include the clinical rationale, relevant test results, and records supporting the requested drug and dose.
    • Provide weight, body surface area, or other member-specific measurement when required for dosing.
    Documentation Required

    Stage 2 Autoantibody Documentation

    Document Stage 2 T1D confirmed by two positive pancreatic islet autoantibodies.

    • Accepted antibodies include GAD, IAA, IA-2A, ZnT8A, and ICA.
    Documentation Required

    Stage 2 Dysglycemia Documentation

    Document dysglycemia without overt hyperglycemia using an oral glucose tolerance test performed within the last 60 days, or provide an accepted alternative method when an OGTT is unavailable.

    • Qualifying findings include fasting glucose 100–125 mg/dL; 2-hour postprandial glucose at least 140 and less than 200 mg/dL; or an intervening 30-, 60-, or 90-minute postprandial glucose greater than 200 mg/dL on two occasions.
    • Document that the clinical history does not suggest type 2 diabetes.
    Documentation Required

    Stage 3 Diagnostic and Beta-Cell Documentation

    For Stage 3 T1D, document recent diagnosis and preserved pancreatic beta-cell function.

    • Diagnosis must be within the past 6 weeks and confirmed by one positive pancreatic islet autoantibody.
    • Document peak C-peptide ≥ 0.2 pmol/mL on a mixed-meal tolerance test, or an accepted alternative assessment of residual beta-cell function when the test is unavailable.
    Documentation Required

    Submit Endocrinology Consultation Notes

    When the prescription is issued in consultation with an endocrinologist, submit the board-certified endocrinologist’s consultation notes with the initial request.

    Documentation Required

    Indication and Age Documentation

    Document the member’s age, Stage 2 or Stage 3 disease classification, and the corresponding FDA-approved treatment indication in the request.

    • Stage 2 treatment applies to members aged 1 year and older.
    • Stage 3 treatment applies to pediatric members aged 8 to 17 years with recently diagnosed Stage 3 T1D.
    Documentation Required

    Baseline Safety Assessment

    Complete and submit baseline laboratory results before treatment to assess whether Tzield is appropriate and safe.

    • Lymphocytes: at least 1,000/mcL; hemoglobin: at least 10 g/dL; platelets: at least 150,000/mcL; absolute neutrophils: at least 1,500/mcL.
    • ALT and AST must not exceed 2 times ULN; bilirubin must not exceed 1.5 times ULN.
    Denial Risk

    Insufficient Documentation Creates Denial Risk

    Insufficient supporting documentation may result in denial or other appropriate action when the request does not establish medical necessity, non-investigational use, benefit eligibility, or appropriate billing and practice.

    • Ensure the submitted records support the initial determination and requested treatment.
    Denial Risk

    Stage 2 Criteria Must Be Met

    Do not submit Stage 2 requests without documentation of qualifying dysglycemia and a clinical history that does not suggest type 2 diabetes.

    • Use an OGTT from within the last 60 days or document an appropriate alternative method.
    • Document qualifying glucose values and the required differential diagnosis.
    Denial Risk

    Stage 3 Criteria Must Be Met

    Do not submit Stage 3 requests without documentation that the diagnosis was made within the past 6 weeks and that preserved beta-cell function is present.

    • Document one positive pancreatic islet autoantibody.
    • Document peak C-peptide ≥ 0.2 pmol/mL on a mixed-meal tolerance test or an accepted alternative assessment.
    Denial Risk

    Non-Approved Use

    Uses outside the FDA-approved indications are considered experimental or investigational and are handled under Molina’s Off-Label policy.

    • Verify the requested disease stage, age, and indication before submitting authorization.
    Denial Risk

    Contraindications and Unsafe Clinical Conditions

    Screen for contraindications and unsafe clinical conditions before requesting or administering Tzield.

    • Do not use in immunocompromised patients or patients with active viral infection, including EBV or CMV.
    • Avoid use in patients with active serious infection or chronic active infection other than localized skin infection.
    • Complete required laboratory screening; avoid treatment when specified blood-count or liver-test thresholds are not met.
    • Give age-appropriate vaccinations before treatment and avoid concurrent live, inactivated, and mRNA vaccines. Monitor for infection and viral reactivation during and after treatment; discontinue Tzield if serious infection or suspected viral reactivation develops.
    Denial Risk

    Pregnancy Restriction

    Avoid Tzield during pregnancy and for at least 30 days before a planned pregnancy.

    • Confirm pregnancy status and planned pregnancy timing before treatment.
    IA-2A, ZnT8A, and ICA
    Stage 1 T1D
    Defining featureAppearance of type 1 diabetes-related autoantibodies
    Glucose statusBefore dysglycemia
    SymptomsBefore symptomatic hyperglycemia
    Stage 2 T1D
    AutoantibodiesTwo or more type 1 diabetes-related autoantibodies
    Glucose statusDysglycemia is present
    Disease statusOccurs before Stage 3 clinical diabetes
    Stage 3 T1D
    Underlying processAutoimmune destruction of beta cells has occurred
    Glucose statusBlood glucose is elevated
    Clinical statusPatients are symptomatic and require insulin treatment
    Mixed-meal tolerance test and alternative C-peptide tests
    Primary testMixed-meal tolerance test measuring C-peptide after stimulation
    Alternative testsGlucagon stimulation, urine C-peptide/creatinine ratio, or fasting C-peptide
    Additional alternativeIntravenous arginine stimulation with serum C-peptide measured before and after
    Diagnosis within the past 6 weeks; peak C-peptide ≥0.2 pmol/mL

    Peak C-peptide must be measured on a mixed-meal tolerance test, or by an appropriate alternative method when unavailable; documentation required

    Initial 14-Day Course

    Covered when ALL of the following are met:

    Initial course: Use is for an FDA-approved indication and administer a single 14-day treatment course by intravenous infusion14 consecutive treatment days

    Do not administer two doses on the same day. If an infusion is missed, resume dosing on consecutive days to complete the 14-day course.

    Tzield Stage 3 treatment schedule
    Number of coursesTwo 12-day courses
    IntervalCourses are administered 6 months apart
    DosingDay 1: 106 mcg/m²; Day 2: 425 mcg/m²; Days 3 through 12: 850 mcg/m²
    Tzield (teplizumab-mzwv)
    Treatment courseOne 14-day treatment course
    AdministrationAdministered by intravenous infusion
    Dose timingDo not administer two doses on the same day